Clinical trials: Platelet Transfusion Refractoriness
Platelet Transfusion Refractoriness
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.
- Trial name
- NCT06792019
- Testing
- CM313(SC) injection-low dose, CM313(SC) injection-high dose
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Keymed Biosciences Co.Ltd
Thrombocytopenia, Hematologic Malignancy
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate…
- Conditions
- Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders
- Trial name
- NCT04631211
- Testing
- Thrombosomes, Liquid Stored Platelets (LSP)
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 21 people
- Sponsor
- Cellphire Therapeutics, Inc.